Clinical Trials
20 trialsNCT06266338 2026-05-06
Study of Pembrolizumab and Lenvatinib in Metastatic and Recurrent Cervix Cancer (LenPem Cervix)
University of Texas Southwestern Medical Center
Phase 2 Recruiting
NCT06157151 2026-04-23
PRGN-2009 in Combination With Pembrolizumab in Patients With Recurrent or Metastatic Cervical Cancer
Precigen, Inc
Phase 2 Recruiting
NCT07223424 2026-04-16
PSI-Immune
University of Pittsburgh
Phase 2 Recruiting
NCT07368985 2026-01-27
Pembrolizumab and Lenvatinib in Patients With High Risk Locally Advanced Cervix Cancer
Erasmus Medical Center
Phase 2 Not yet recruiting
NCT07054567 2026-01-21
A Study of BL-B01D1 + Pembrolizumab ± Bevacizumab in Patients With Recurrent or Metastatic Cervical Cancer and Endometrial Cancer
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 2 Recruiting
NCT03228667 2026-01-14
QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitors
ImmunityBio, Inc.
Phase 2 Active not recruiting
NCT06640283 2025-12-24
ANA
Instituto do Cancer do Estado de São Paulo
Phase 2 Recruiting
NCT04865887 2025-10-07
Pembrolizumab and Lenvatinib in Advanced Cervical Cancer
Georgetown University
Phase 2 Recruiting
NCT02628067 2025-09-22
KEYNOTE 158
Merck Sharp & Dohme LLC
Phase 2 Active not recruiting
NCT03108495 2025-09-17
Study of LN-145, Autologous Tumor Infiltrating Lymphocytes in the Treatment of Patients With Cervical Carcinoma
Iovance Biotherapeutics, Inc.
Phase 2 Terminated
NCT05007106 2025-08-14
KEYVIBE-005
Merck Sharp & Dohme LLC
Phase 2 Completed
NCT02635360 2025-07-03
Pembrolizumab and Chemoradiation Treatment for Advanced Cervical Cancer
University of Virginia
Phase 2 Completed
NCT04483544 2025-04-29
Pembrolizumab and Olaparib in Cervical Cancer Patients
Baptist Health South Florida
Phase 2 Terminated
NCT04357873 2025-02-19
PEVOsq
UNICANCER
Phase 2 Completed
NCT06805864 2025-02-03
BROTHER
Gunma University
Phase 2 Not yet recruiting
NCT03367871 2024-06-18
Combination Pembrolizumab, Chemotherapy and Bevacizumab in Patients With Cervical Cancer
University of Miami
Phase 2 Terminated
NCT04641728 2022-08-09
Pembrolizumab Plus Olaparib in Patients With Recurrent Cervical Cancer
Saitama Medical University International Medical Center
Phase 2 Unknown
NCT04230954 2022-06-07
Cabozantinib Plus Pembrolizumab for Recurrent, Persistent and/or Metastatic Cervical Cancer
University of South Alabama
Phase 2 Terminated
NCT03192059 2021-09-08
PRIMMO
University Hospital, Ghent
Phase 2 Completed
NCT03544723 2020-06-09
Safety and Efficacy of p53 Gene Therapy Combined With Immune Checkpoint Inhibitors in Solid Tumors.
MultiVir, Inc.
Phase 2 Unknown